PEPTIDES
Ascletis Says Its Triple Agonist Outlasts Retatrutide Sixfold. The Evidence Is Still Monkeys and Mice.
Retatrutide half life is one of the most searched technical questions about Eli Lilly's experimental triple agonist, and for good reason: the amount of...
PEPTIDES
Novo Says 40% of Young Kids on Semaglutide Fell Below the Obesity Line. The Full Data Arrive Nov. 16
Parents type "Ozempic for kids" into search bars. The drug they are asking about is semaglutide, and the clinical trial they need to understand...
PEPTIDES
Novo Was Sued Over How CagriSema Was Dosed. Its Next Readout Tests Lower Doses.
CagriSema's first major obesity trial produced substantial weight loss, but it also left Novo Nordisk answering questions about how many participants reached the highest...
PEPTIDES
Viking’s “97%” Came From 12 People. VK2735’s Real Test Is Already Enrolled.
Viking Therapeutics says one dosing arm in its maintenance study retained 97% of its earlier weight loss.
That arm had 12 people in it.
The figure...
PEPTIDES
KPV Made HHS’s Peptide List. FDA Says It Found No Human Data.
KPV is just three amino acids long. It is now one of six peptides covered by a limited U.S. Department of Health and Human...
PEPTIDES
Why Semaglutide Lasts a Week When Natural GLP-1 Lasts Minutes
The hormone that inspired one of the biggest drug classes of the decade barely survives in human circulation.
Natural glucagon-like peptide-1, or GLP-1, is rapidly...
PEPTIDES
MariTide’s Heart and Sleep Apnea Trials Are Full. Amgen Still Hasn’t Shown Phase 3 Results
Amgen's third-quarter report on November 3 was mostly about a large, profitable company doing what large, profitable companies do: $10.4 billion in revenue, up...
PEPTIDES
Rhythm’s Hunger Peptide Just Had Its Biggest Quarter. Now Rhythm Is Borrowing Against It
Most obesity-drug stories this year have been measured in billions of dollars and double-digit percentages of body weight lost.
Rhythm Pharmaceuticals has been running a...
